Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Swedish Orphan Biovitrum Ab (BIOVF)

Swedish Orphan Biovitrum Ab (BIOVF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Swedish Orphan Biovitrum Ab Tomtebodavagen 93 A Solna Stockholm V7 SE-112 76 SWE

www.sobi.com Employees: 1,937 P: 46-8697-2000

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company's product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden.

Key Statistics

Overview:

Market Capitalization, $K 12,549,000
Enterprise Value, $K 13,986,260
Shares Outstanding, K 356,000
Annual Sales, $ 2,462 M
Annual Net Income, $ 367,520 K
Last Quarter Sales, $ 817,260 K
Last Quarter Net Income, $ -304,160 K
EBIT, $ -20,710 K
EBITDA, $ 327,320 K
60-Month Beta 0.38
% of Institutional Shareholders 0.00%
Float, K 356,000
% Float 100.00%
Short Volume Ratio 1.00

Growth:

1-Year Return 26.16%
3-Year Return 116.79%
5-Year Return 0.00%
5-Year Revenue Growth 63.33%
5-Year Earnings Growth -12.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.64 on 10/20/25
Next Earnings Date 10/23/25
Earnings Per Share ttm 1.51
EPS Growth vs. Prev Qtr 166.67%
EPS Growth vs. Prev Year 60.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

BIOVF Ratios

Ratio
Price/Earnings ttm 23.10
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 13.66%
Return-on-Assets % 7.50%
Profit Margin % 14.93%
Debt/Equity 0.37
Price/Sales 5.04
Price/Cash Flow 17.18
Price/Book 3.32
Book Value/Share 10.62
Interest Coverage 4.38
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar